File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1053/ejvs.2001.1549
- Scopus: eid_2-s2.0-0036134656
- PMID: 11748944
- WOS: WOS:000173794100005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Prevention of experimental myointimal hyperplasia by immunomodulation
Title | Prevention of experimental myointimal hyperplasia by immunomodulation |
---|---|
Authors | |
Keywords | Immunotherapy Myobacterium vaccae Myointimal hyperplasia Restenosis |
Issue Date | 2002 |
Publisher | WB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejvs |
Citation | European Journal Of Vascular And Endovascular Surgery, 2002, v. 23 n. 1, p. 23-28 How to Cite? |
Abstract | Introduction: we have tested the hypothesis that treatment with a mycobacterial preparation that modulates the antibody response, would diminish restenosis in a rat angioplasty model. Materials/Methods: male Sprague-Dawley rats were used. All immunisations were given subcutaneously. Group A (control) received normal saline on days 0, 21, and 42. Group B received SRL172 on days 0, 21, and 42. Group C received SRL172 on days 0, 21, and 42, and hsp65/Incomplete Freund's on days 21 and 42. Group D received hsp65/ Freund's on days 21 and 42. Right common carotid arteries were balloon-injured on day 63 using a standard technique known to produce MIH and animals were sacrificed on day 77. For each carotid 6 μm cross sections were cut from paraffin blocks. Cross-sectional areas were measured by computerised planimetry. Results: balloon injury resulted in MIH in all animals. Data represents mean ± SEM for the percentage of area enclosed within the internal elastic lamina occupied by MIH (% MIH); which for groups A, B, C, and D was 85 ± 11, 24 ± 3, 27 ± 7, and 17 ± 3 respectively. All the treatment groups had significantly less MIH when compared to the control group but no statistically significant difference was found between any of the treatment groups. Conclusions: this is the first report that immunomodulation with mycobacterial material suitable for use in man, can reduce MIH. Since such modulation has low risk, this raises the prospect of an important new therapeutic modality to combat restenosis. © 2002 Harcourt Publishers Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/147675 |
ISSN | 2023 Impact Factor: 5.7 2023 SCImago Journal Rankings: 1.330 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Stansby, G | en_HK |
dc.contributor.author | Chan, YC | en_HK |
dc.contributor.author | Berwanger, CS | en_HK |
dc.contributor.author | Shurey, S | en_HK |
dc.contributor.author | Rook, GAW | en_HK |
dc.contributor.author | Stanford, JL | en_HK |
dc.date.accessioned | 2012-05-29T06:07:52Z | - |
dc.date.available | 2012-05-29T06:07:52Z | - |
dc.date.issued | 2002 | en_HK |
dc.identifier.citation | European Journal Of Vascular And Endovascular Surgery, 2002, v. 23 n. 1, p. 23-28 | en_HK |
dc.identifier.issn | 1078-5884 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/147675 | - |
dc.description.abstract | Introduction: we have tested the hypothesis that treatment with a mycobacterial preparation that modulates the antibody response, would diminish restenosis in a rat angioplasty model. Materials/Methods: male Sprague-Dawley rats were used. All immunisations were given subcutaneously. Group A (control) received normal saline on days 0, 21, and 42. Group B received SRL172 on days 0, 21, and 42. Group C received SRL172 on days 0, 21, and 42, and hsp65/Incomplete Freund's on days 21 and 42. Group D received hsp65/ Freund's on days 21 and 42. Right common carotid arteries were balloon-injured on day 63 using a standard technique known to produce MIH and animals were sacrificed on day 77. For each carotid 6 μm cross sections were cut from paraffin blocks. Cross-sectional areas were measured by computerised planimetry. Results: balloon injury resulted in MIH in all animals. Data represents mean ± SEM for the percentage of area enclosed within the internal elastic lamina occupied by MIH (% MIH); which for groups A, B, C, and D was 85 ± 11, 24 ± 3, 27 ± 7, and 17 ± 3 respectively. All the treatment groups had significantly less MIH when compared to the control group but no statistically significant difference was found between any of the treatment groups. Conclusions: this is the first report that immunomodulation with mycobacterial material suitable for use in man, can reduce MIH. Since such modulation has low risk, this raises the prospect of an important new therapeutic modality to combat restenosis. © 2002 Harcourt Publishers Ltd. | en_HK |
dc.language | eng | en_US |
dc.publisher | WB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejvs | en_HK |
dc.relation.ispartof | European Journal of Vascular and Endovascular Surgery | en_HK |
dc.subject | Immunotherapy | en_HK |
dc.subject | Myobacterium vaccae | en_HK |
dc.subject | Myointimal hyperplasia | en_HK |
dc.subject | Restenosis | en_HK |
dc.subject.mesh | Adjuvants, Immunologic - Therapeutic Use | en_US |
dc.subject.mesh | Angioplasty, Balloon | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antigens, Bacterial - Immunology | en_US |
dc.subject.mesh | Bacterial Proteins | en_US |
dc.subject.mesh | Bacterial Vaccines - Therapeutic Use | en_US |
dc.subject.mesh | Carotid Artery Injuries | en_US |
dc.subject.mesh | Carotid Artery, Common - Pathology | en_US |
dc.subject.mesh | Carotid Stenosis - Pathology - Prevention & Control - Therapy | en_US |
dc.subject.mesh | Chaperonin 60 | en_US |
dc.subject.mesh | Chaperonins - Immunology | en_US |
dc.subject.mesh | Constriction, Pathologic | en_US |
dc.subject.mesh | Hyperplasia | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Muscle, Smooth, Vascular - Pathology | en_US |
dc.subject.mesh | Mycobacterium - Immunology | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, Sprague-Dawley | en_US |
dc.subject.mesh | Recurrence | en_US |
dc.subject.mesh | Tunica Intima - Pathology | en_US |
dc.subject.mesh | Vaccines, Inactivated - Therapeutic Use | en_US |
dc.title | Prevention of experimental myointimal hyperplasia by immunomodulation | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Chan, YC: ycchan88@hkucc.hku.hk | en_HK |
dc.identifier.authority | Chan, YC=rp00530 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1053/ejvs.2001.1549 | en_HK |
dc.identifier.pmid | 11748944 | - |
dc.identifier.scopus | eid_2-s2.0-0036134656 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0036134656&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 23 | en_HK |
dc.identifier.issue | 1 | en_HK |
dc.identifier.spage | 23 | en_HK |
dc.identifier.epage | 28 | en_HK |
dc.identifier.isi | WOS:000173794100005 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Stansby, G=7004963829 | en_HK |
dc.identifier.scopusauthorid | Chan, YC=27170769400 | en_HK |
dc.identifier.scopusauthorid | Berwanger, CS=6701673031 | en_HK |
dc.identifier.scopusauthorid | Shurey, S=6508143053 | en_HK |
dc.identifier.scopusauthorid | Rook, GAW=7102196411 | en_HK |
dc.identifier.scopusauthorid | Stanford, JL=7202266598 | en_HK |
dc.identifier.issnl | 1078-5884 | - |